ASMB Assembly Biosciences, Inc

XNAS 19.67 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ASMB $19.67 —
Key stats
$19.67
52-Week Range
$19.30 – $39.70
YTD
-41.71%
IV Rank (30D)
93.69
Straddle Price
$5.10
P/C Vol Ratio
0.03
Market Cap
$0.4B
Open
$19.97
Day Range
$19.59 – $20.09
Volume
152,227
Prev Close
$19.84
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.12
Cost of Equity (CAPM)11.13% (VRP-adj)
WACC11.27%
Volatility Risk Premium+66.2pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-0.0%
Book / Price83.4% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-54.2%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$27.09 (Market Anchor value)
SMA 20 / Bollinger Mid$21.63
Bollinger Width / SMA20118.0% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
71%
20-Day Fair Value
≈ by Nov 25, 2026
$19.76
α +0.5% rank 87%
conviction
29%
40-Day Fair Value
≈ by Dec 24, 2026
$19.82
α +0.8% rank 90%
conviction
25%
60-Day Fair Value
≈ by Jan 22, 2027
$20.15
α +2.4% rank 89%
conviction
71%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.5× · 3 peers
Peer EV/EBITDA n/a 0% median 19.2× · 3 peers
Peer P/B $57.55 16% median 3.5× · 3 peers
Peer P/S $22.60 16% median 3.9× · 3 peers
Market Anchor (SMA50) $27.09 69% stability 85% (BB-width)
Options Expected (B-L 30d) $19.09 0% 8 strikes · skew -0.13
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.4B
Employees
73
List Date
2010-12-17
CIK
0001426800
Next Earnings
2026-11-09 (After-Close)
EPS Forecast
($0.44) (1 est.)
Headquarters
South San Francisco, CA
Homepage
https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the tre…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-7.62%-24.08%29.85%12.99%-18.31%-23.62%-5.13%
Feb-12.26%-17.99%-20.93%12.56%-6.67%13.16%-5.35%
Mar-8.91%34.64%-39.10%-1.26%-21.83%-6.50%-7.16%
Apr-6.14%-14.56%23.96%-3.33%21.30%-8.43%2.13%
May-4.57%6.70%-7.01%14.17%23.69%1.06%5.67%
Jun-3.72%12.30%20.07%-8.23%17.66%2.08%6.69%
Jul-9.16%-5.48%3.74%10.31%1.10%-5.53%-0.84%
Aug9.51%-6.97%-9.18%13.31%34.24%32.61%12.25%
Sep-10.77%-15.03%-9.69%-4.36%6.09%-33.23%-11.16%
Oct-8.96%-1.20%3.16%13.66%26.17%-14.40%*3.07%
Nov-27.67%-20.61%-21.07%0.89%21.24%---9.44%
Dec4.02%0.00%14.54%-5.79%0.35%--2.62%
Total-61.29%-49.70%-31.33%64.26%132.53%-45.34%1.52%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $21.63
SMA 50: $27.09
SMA 200: $27.42
Current: $19.67
EMA 12: $20.83
EMA 26: $22.60
MACD: -1.7706 | Signal: 0.0995
BEARISH
ADX (14): 45.55
STRONG TREND
+DI: 12.93
−DI: 30.74

Momentum Oscillators

RSI (14): 29.37
OVERSOLD
Stoch %K: 9.61
Stoch %D: 13.01
Williams %R: -91.83

Volume & Volatility

BB Upper: $24.39
BB Lower: $18.87
NEUTRAL
OBV: 5,123,238
Vol SMA 20: 234,287
Vol ROC: -26.75%
ATR: $1.15
True Range: $0.50
HV 20: 52.6%
HV 30: 53.7%
HV 60: 63.8%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall assessment: BEARISH with confidence level (7/10)

Key drivers:

  • Strong momentum signal from MACD
  • Weak RSI reading indicating potential oversold conditions
  • Negative news sentiment and catalyst timeline aligning with technical signals

Primary risks:

  • High volatility as indicated by beta and stock volatility metrics
  • Bearish options market sentiment

Investment thesis: ASMB's recent price action is driven by a combination of negative news sentiment and weak momentum indicators. While the stock has shown some strength, the bearish MACD signal and oversold RSI reading suggest potential for further declines.

Recent news sentiment impact: The positive news headlines are not sufficient to counterbalance the overall bearish market narrative, which aligns with the technical analysis.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): BEARISH; Medium-term (1-3 months): NEUTRAL; Long-term (3-12 months): BULLISH

Support/Resistance Levels: $33.53 (SMA 20), $29.37 (SMA 50)

Momentum Signals:

  • RSI interpretation: Overbought (>70) at 67.18, indicating potential sell signal
  • MACD signal: Bullish momentum is weak, but still present
  • Bollinger Bands position: Neutral

Volume Analysis: Volume trends are bearish, and institutional interest signals are mixed.

News & Sentiment Analysis

Recent Headlines Summary: The news headlines are mostly positive, but the overall sentiment remains bearish due to the focus on recent declines.

Sentiment Assessment: Aggregate news sentiment is NEUTRAL (50:50).

Catalyst Identification: None significant in the near term.

Market Narrative: The technical analysis suggests a potential short-term decline, which aligns with the market narrative.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to market (beta >1.25)

Volatility Regime: High volatility, as indicated by the stock's beta and historical volatility metrics.

Options Market Signals: IV rank is low (0.0%), indicating historically low volatility; put/call ratios are bearish.

Downside Protection: Support levels at $33.53 and $29.37 should be monitored for potential buy signals.

Market Context & Positioning

Sector Performance: ASMB's sector is performing relatively weakly.

Institutional Activity: Mixed volume patterns suggest institutional interest is not significant.

Correlation Analysis: The stock's correlation with the market is low (0.27).

Relative Valuation: Position within trading range, which could be supportive of a short-term bounce.

Key Levels & Action Items

Critical Price Levels: Support at $33.53 and resistance at $39.16 should be monitored.

Breakout/Breakdown Levels: A breakdown below $29.37 could trigger significant declines.

Time-Sensitive Catalysts: No immediate catalysts are present, but the stock's beta suggests potential for high volatility.

Risk Management: Consider stop-loss levels at $34.50 and position sizing considering the high risk profile.

Please note that this is a hypothetical analysis and not an actual investment recommendation.

Generated
Earnings History
7 of 8 under expected move
Avg Expected Move
34.91%
Avg Actual Move
5.52%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-25 After-Close 0.68% 8.14% 11.97x Exceeded
2021-05-06 After-Close 23.89% 3.57% 0.15x Within
2022-08-09 After-Close 2.12% 0.46% 0.22x Within
2023-11-08 After-Close 180.65% 12.48% 0.07x Within
2025-11-10 After-Close 18.09% 3.31% 0.18x Within
2026-03-19 After-Close 24.72% 3.45% 0.14x Within
2026-05-07 After-Close 16.57% 3.85% 0.23x Within
2026-08-14 After-Close 12.52% 8.92% 0.71x Within

Earnings calendar: this week’s reports with expected vs actual moves →

ASMB Options Activity & IV Rank

ASMB IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 113.3%
7-DTE IV: —
Expected Move: $5.10
7-DTE Move: $5.10
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 382
Put Volume: 10
P/C Volume: 0.026
BULLISH
Call OI: 659
Put OI: 60
P/C OI: 0.091
Total OI: 719

ATM Options Pricing

ATM Call: $2.60
ATM Put: $2.50
Call %: 13.2%
Put %: 12.7%

Chain Summary

Chain Volume: 1,005
Chain OI: 2,542
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 65th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
65%
vs own history
GEX tilt
+0.71
OI-weighted, today
Vanna tilt
+0.78
δ-sensitivity to IV
Charm tilt
-0.83
δ-decay vs time
Vanna tilt +0.78: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.83: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 7 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 123.2% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)93.7HighOct 26
Straddle Price (30 DTE)$5.10Oct 26
Beta Analysis

Risk Metrics

Beta: 1.2897
Alpha: -39.35%
Correlation: 0.2794
R-Squared: 7.8%
Stock Volatility: 58.8%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ASMB
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Point72 Hedge fund
Steve Cohen
$12.7M
0.02%
#697 of 1945+33.9%13F
Millennium Management Hedge fund
Izzy Englander
$8.2M
0.01%
#1723 of 3716+27.9%13F
Citadel Hedge fund
Ken Griffin
$2.6M
0.00%
#2636 of 6285+277.0%13F
Renaissance Technologies Hedge fund
Jim Simons
$1.1M
0.00%
#2275 of 3138+152.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ASMB Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 12,113,285 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

99 filers20,189,190 shares$558.20M value166.67% of float
# Filer Shares Value % of Total % of Float Period
1 GILEAD SCIENCES, INC. 4,977,089 $136.77M 24.50% 41.09% 2026-06-30
2 FARALLON CAPITAL MANAGEMENT, L.L.C. 1,604,590 $44.09M 7.90% 13.25% 2026-06-30
3 Paradigm Biocapital Advisors LP 1,553,748 $42.70M 7.65% 12.83% 2026-06-30
4 Commodore Capital LP 1,415,000 $38.88M 6.97% 11.68% 2026-06-30
5 RA CAPITAL MANAGEMENT, L.P. 1,020,410 $28.04M 5.02% 8.42% 2026-06-30
6 Janus Henderson Group plc 849,309 $23.48M 4.21% 7.01% 2026-03-31
7 Jupiter Topco LLC 849,309 $23.37M 4.19% 7.01% 2026-06-30
8 BlackRock, Inc. Custodian 766,819 $21.07M 3.77% 6.33% 2026-06-30
9 Parkman Healthcare Partners LLC 721,181 $19.82M 3.55% 5.95% 2026-06-30
10 Vanguard Group Inc Custodian 572,898 $19.48M 3.49% 4.73% 2025-12-31
11 Vanguard Capital Management LLC 558,942 $15.36M 2.75% 4.61% 2026-06-30
12 Point72 Asset Management, L.P. 460,593 $12.66M 2.27% 3.80% 2026-06-30
13 Seven Fleet Capital Management LP 433,147 $11.90M 2.13% 3.58% 2026-06-30
14 Millennium Management LLC Custodian 298,807 $8.21M 1.47% 2.47% 2026-06-30
15 Geode Capital Management, LLC Custodian 280,424 $7.71M 1.38% 2.31% 2026-06-30
16 Schonfeld Strategic Advisors LLC 242,153 $6.65M 1.19% 2.00% 2026-06-30
17 Ameriprise Financial, Inc. Custodian 230,000 $6.32M 1.13% 1.90% 2026-06-30
18 DV EQUITIES, LLC 226,415 $6.22M 1.11% 1.87% 2026-06-30
19 Aberdeen Group plc 207,047 $5.69M 1.02% 1.71% 2026-06-30
20 Affinity Asset Advisors, LLC 190,000 $5.22M 0.94% 1.57% 2026-06-30
21 B Group, Inc. 175,706 $4.83M 0.86% 1.45% 2026-06-30
22 State Street Corp 171,931 $4.72M 0.85% 1.42% 2026-06-30
23 STEMPOINT CAPITAL LP 170,378 $4.68M 0.84% 1.41% 2026-06-30
24 Squadron Capital Management LLC 160,000 $4.40M 0.79% 1.32% 2026-06-30
25 Woodline Partners LP 150,780 $4.14M 0.74% 1.24% 2026-06-30
3 filers$758.45K notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $508.38K 67.03% 2026-06-30
2 Susquehanna International Group, LLP Custodian $239.08K 31.52% 2026-06-30
3 Simplex Trading, LLC Custodian $10.99K 1.45% 2026-06-30
1 filers$502.88K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $502.88K 100.00% 2026-06-30

ASMB Insider Trading (Form 4)

Latest: 2026-06-18
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-06-18 Jeanette M Bjorkquist PFO and PAO Sell (S) −29 $23.25 -$674 EDGAR
2026-06-05 Gina Consylman Director Grant (A) +8,000 opt — EDGAR
2026-06-05 Anthony E Altig Director Grant (A) +8,000 opt — EDGAR
2026-06-05 Susan Mahony Director Grant (A) +8,000 opt — EDGAR
2026-06-05 Jeanette M Bjorkquist PFO and PAO Award (A) +3,500 — EDGAR
2026-06-05 William E Delaney IV Chief Scientific Officer Award (A) +14,000 — EDGAR
2026-06-05 John G McHutchison Director Grant (A) +8,000 opt — EDGAR
2026-06-05 Nicole S White Chief Manufacturing Officer Award (A) +14,000 — EDGAR
2026-06-05 Michael Houghton Director Grant (A) +8,000 opt — EDGAR
2026-06-05 Jason A Okazaki CEO and President Award (A) +50,750 — EDGAR
2026-06-05 Lisa Johnson-Pratt Director Grant (A) +8,000 opt — EDGAR
2026-06-05 Anuj Gaggar Chief Medical Officer Award (A) +14,000 — EDGAR
2026-05-27 GILEAD SCIENCES, INC. 10%+ Owner Award (A) +471,698 $26.50 $12.50M EDGAR
2025-10-03 GILEAD SCIENCES, INC. 10%+ Owner Buy (P) +2,295,920 — EDGAR
2025-06-17 Jeanette M Bjorkquist PFO and PAO Award (A) +300 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ASMB Insider Holdings

11 insiders · @ $19.67
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 GILEAD SCIENCES, INC. 10%+ Owner 4,977,089 $97.90M $20.10M 4 2026-05-27
2 Alexander Schornstein 10%+ Owner 720,137 $14.17M $1.42M 5 2024-11-26
3 Jason A Okazaki CEO and President 163,354 $3.21M -$101.1K 20 2026-06-05
4 William E Delaney IV Chief Scientific Officer 60,330 $1.19M -$52.4K 17 2026-06-05
5 Nicole S White Chief Manufacturing Officer 48,145 $947.0K -$39.0K 10 2026-06-05
6 Anuj Gaggar Chief Medical Officer 42,688 $839.7K $0 3 2026-06-05
7 John G McHutchison Director 18,347 $360.9K -$439.0K 17 2026-06-05
8 Jeanette M Bjorkquist PFO and PAO 14,560 $286.4K -$6.1K 9 2026-06-18
9 Michael Houghton Director 3,202 $63.0K $50.0K 7 2026-06-05
10 William R Ringo Director 1,455 $28.6K -$510.4K 23 2025-06-09
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ASMB Board & Officers

As of SEC filings through Jun 18, 2026

Directors 10

Officers 5

10% owners 1

Changes in the last 10 years (34)
Jun 17, 2025Jeanette M Bjorkquist listed as PFO and PAO (previously Principal Accounting Officer) in SEC filings
Mar 13, 2024Robert Donald Cook II became a director
Dec 7, 2023Tomas Cihlar became a director
Nov 8, 2023Anuj Gaggar became Chief Medical Officer
Oct 23, 2023Alexander Schornstein became a 10% owner
Oct 16, 2023Gilead Sciences, Inc. became a 10% owner
Sep 13, 2023Nicole S White became Chief Manufacturing Officer
Feb 17, 2023Jason A Okazaki listed as CEO and President (previously Chief Operating Officer) in SEC filings
Feb 17, 2023Jason A Okazaki first listed as a director in an SEC filing
Oct 5, 2022The company announced the departure of John G McHutchison as CEO and President in an SEC filing
Sep 9, 2022Jeanette M Bjorkquist became Principal Accounting Officer
Jul 19, 2022The company announced the departure of Michael P. Samar as Chief Financial Officer in an SEC filing
Mar 31, 2022Michael P. Samar listed as Chief Financial Officer (previously SVP, Fin. & Bus. Ops, PFO, PAO) in SEC filings
Mar 29, 2022Jason A Okazaki listed as Chief Operating Officer (previously Chief Legal & Business Officer) in SEC filings
Jul 19, 2021Michael Houghton became a director
Jun 4, 2021Michael P. Samar listed as SVP, Fin. & Bus. Ops, PFO, PAO (previously SVP, Finance and Bus. Ops, PAO) in SEC filings
May 20, 2021Lisa Johnson-Pratt became a director
Apr 2, 2021William E Delaney IV listed as Chief Scientific Officer (previously CSO, Virology) in SEC filings
Oct 19, 2020Gina Consylman became a director
May 27, 2020William E Delaney IV became CSO, Virology
Not reported recently (16)
  • Alexander Schornstein · Last reported as a 10% owner in an SEC filing dated Nov 26, 2024
  • Richard D DiMarchi · Last reported as a director in an SEC filing dated May 27, 2022
  • Luisa M Stamm · Last reported as Chief Medical Officer in an SEC filing dated Mar 31, 2022
  • Myron Z Holubiak · Last reported as a director in an SEC filing dated May 24, 2021
  • Thomas Joseph Russo · Last reported as CFO in an SEC filing dated Apr 2, 2021
  • Jacqueline Sybil Papkoff · Last reported as SVP-CSO Microbiome in an SEC filing dated Dec 15, 2020
  • Alan Lewis · Last reported as a director in an SEC filing dated Jun 15, 2020
  • Helen Susan Kim · Last reported as a director in an SEC filing dated Jun 15, 2020
  • Richard James Colonno · Last reported as EVP & CSO, Virology Ops in an SEC filing dated Mar 31, 2020
  • Derek A Small · Last reported as a director in an SEC filing dated Jan 3, 2020
  • Mark Auerbach · Last reported as a director in an SEC filing dated May 17, 2019
  • Uri A Lopatin · Last reported as Chief Med. Off., VP Res. Dev. in an SEC filing dated Apr 2, 2019
  • Graham K Cooper · Last reported as Chief Financial Officer and Chief Operating Officer in an SEC filing dated Apr 2, 2019
  • EcoR1 Capital Fund Qualified, L.P. · Last reported as a 10% owner in an SEC filing dated Apr 18, 2018
  • Thomas E Rollins · Last reported as Chief Development Officer & Head of Microbiome Program in an SEC filing dated Mar 30, 2018
  • David Jonathan Barrett · Last reported as Chief Financial Officer in an SEC filing dated Mar 31, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

ASMB Proposed Insider Sales (Form 144)

Latest: 2023-10-03
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2023-10-03 William E. Delaney IV Officer 1,891 $1.6K 2023-10-03 Morgan Stanley Smith Barney LLC — EDGAR
2023-10-03 Jason A. Okazaki Officer, Director 2,363 $2.0K 2023-10-03 Morgan Stanley Smith Barney LLC — EDGAR
2023-08-02 Jason Okazaki Officer, Director 11,827 $12.9K 2023-08-02 Morgan Stanley Smith Barney LLC — EDGAR
2023-08-02 William E. Delaney IV Officer 9,461 $10.3K 2023-08-02 Morgan Stanley Smith Barney LLC — EDGAR
2023-05-30 William E. Delaney IV Officer 4,232 $4.0K 2023-05-30 Morgan Stanley Smith Barney LLC — EDGAR
2023-05-23 William E. Delaney IV Officer 6,561 $6.8K 2023-05-23 Morgan Stanley Smith Barney LLC — EDGAR
2023-05-23 Jason Okazaki Officer, Director 6,561 $6.8K 2023-05-23 Morgan Stanley Smith Barney LLC — EDGAR
2023-05-23 John G. McHutchison Director 25,972 $27.0K 2023-05-23 Morgan Stanley Smith Barney LLC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
22 ETFs hold ASMB
22 shown · $35.00M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $10.1M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.01% $6.6M $74.6B 2026-10-23
3 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.06% $6.4M $10.4B 2026-10-23
4 VXF Vanguard Extended Market ETF Vanguard 0.00% $3.8M — 2026-09-30
5 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.02% $2.5M $13.9B 2026-10-23
6 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $1.8M — 2026-09-30
7 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.07% $811,833 $1.2B 2026-10-23
8 VHT Vanguard Health Care ETF Vanguard 0.00% $785,811 — 2026-09-30
9 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.01% $459,375 $6.6B 2026-10-23
10 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.01% $357,418 $3.2B 2026-10-23
11 BBC Virtus Biotech Clinical Trials Etf Nport 0.73% $339,914 — 2026-07-31
12 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.02% $290,336 — 2026-09-30
13 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.04% $247,643 — 2026-10-26
14 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.02% $197,249 $1.0B 2026-10-23
15 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.01% $168,639 — 2026-07-31
16 RSSL Global X Russell 2000 ETF Global X 0.01% $126,635 — 2026-10-26
17 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $30,067 — 2026-09-30
18 ITWO ProShares Russell 2000 High Income ETF ProShares 0.01% $15,028 — 2026-10-26
19 URTY ProShares UltraPro Russell2000 ProShares 0.00% $11,507 — 2026-10-26
20 UWM ProShares Ultra Russell2000 ProShares 0.00% $8,124 — 2026-10-26
21 HDG ProShares Hedge Replication ETF ProShares 0.00% $315 — 2026-10-26
22 RB ProShares Russell 2000 Dynamic Buffer ETF ProShares 0.01% $79 — 2026-10-26
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.11
TTM Revenue
$71.10M
TTM Net Income
$-6.38M
TTM Op. Cash Flow
$-39.75M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31$8.21M$-9.08M$-0.54$-22.10M
Q4 '252025-12-31$42.47M$22.09M$2.48$14.24M
Q3 '252025-09-30$10.79M$-9.20M$-0.72$-15.13M
Q2 '252025-06-30$9.63M$-10.20M$-1.33$-16.76M
Q1 '252025-03-31$9.42M$-8.82M$-1.17$-23.44M
Q4 '242024-12-31$7.36M$-10.34M$-1.57$-407.00K
Q3 '242024-09-30$6.84M$-9.61M$-1.51$-15.24M
Q2 '242024-06-30$8.53M$-11.15M$-1.98$-17.10M
Q1 '242024-03-31$5.79M$-9.08M$-1.66$-18.36M
Q4 '232023-12-31$7.16M$-10.96M$-1.77$73.65M
Q3 '232023-09-30—$-14.42M$-3.29$-13.85M
Q2 '232023-06-30—$-16.90M$-3.88$-13.63M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-07
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.20
P/S
3.35
EV/EBITDA
—
EV/Sales
2.91
ROE
-3.2%
ROA
-2.7%
Div Yield
0.00%
FCF Yield
-16.68%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$238.27M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
2.82M
SI % of Float
27.13%
Days to Cover
6.83
Short Vol Ratio
62.2%
Free Float
10.40M
Float %
65.5%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-19